0
No hay productos en el carro de la compra
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Casa > Protein > LILRB1 > CDJ-H82F7

Biotinylated Human LILRB1 / CD85j / ILT2 Protein, Fc,Avitag™

Order Now

  • Synonym
    CD85J,LILRB1,CD85,ILT2,LIR1,MIR7
  • Source
    Biotinylated Human LILRB1, Fc,Avitag(CDJ-H82F7) is expressed from human 293 cells (HEK293). It contains AA Gly 24 - His 458 (Accession # D9IDM8-1).
    Predicted N-terminus: Gly 24
  • Molecular Characterization
    LILRB1 Structure

    This protein carries a human IgG1 Fc tag at the C-terminus, followed by a Avi tag (Avitag™)

    The protein has a calculated MW of 75.6 kDa. The protein migrates as 100-116 kDa under reducing (R) condition, and 150 kDa under non-reducing (NR) condition (SDS-PAGE) due to glycosylation.

  • Labeling
    Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
  • Protein Ratio
    Passed as determined by the HABA assay / binding ELISA.
  • Endotoxin
    Less than 1.0 EU per μg by the LAL method.
  • Purity

    >95% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
SDS-PAGE
LILRB1 SDS-PAGE

Biotinylated Human LILRB1, Fc,Avitag on SDS-PAGE under reducing (R) and non-reducing (NR) conditions. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

  • Background
    LILRB1 (Uniprot No. D9IDM8-1) is a variant that correlates with the low expression of LILRB1 on NK cells. It reflects the diversity of the LILRB1 locus and its influences on expression patterns on NK cells. LILRB1 belongs to the subfamily B class of LIR receptors which contain two or four extracellular immunoglobulin domains, a transmembrane domain, and two to four cytoplasmic immunoreceptor tyrosine-based inhibitory motifs (ITIMs). The receptor is expressed on immune cells where it binds to MHC class I molecules on antigen-presenting cells and transduces a negative signal that inhibits stimulation of an immune response. It is thought to control inflammatory responses and cytotoxicity to help focus the immune response and limit autoreactivity.
  • Clinical and Translational Updates

Comments (0)


ETA de productos en stock: 2 días laborables

Price(EUR) : €370.00

Price(EUR) : €1610.00

Recommended Products
Placa recubierta de estreptavidina

Price(EUR) : €30.00

Price(EUR) : €140.00

Estreptavidina-HRP

Price(EUR) : €50.00

Price(EUR) : €120.00

Perlas magnéticas™ Estreptavidina

Price(EUR) : €140.00

Price(EUR) : €230.00

Promotion & Exhibitions



Drug Development Status

  • Number of Launched Drugs:0 Details
  • Number of Drugs in Clinical Trials:4 Details
  • Latest Research Phase:Phase 2 Clinical

Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

Related Products

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop
Email
Correo electrónico
Fax
Fax
+1 888-377-6111
Address
Address
Lichtstrasse 35,4056 Basel, Switzerland

Dejar un mensaje